Dianthus Therapeutics Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that target… Read more
Dianthus Therapeutics Inc. (DNTH) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.095x
Based on the latest financial reports, Dianthus Therapeutics Inc. (DNTH) has a cash flow conversion efficiency ratio of -0.095x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-46.98 Million) by net assets ($493.40 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Dianthus Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Dianthus Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Dianthus Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dianthus Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alignment Healthcare LLC
NASDAQ:ALHC
|
-0.281x |
|
Walsin Lihwa Corp
TW:1605
|
0.021x |
|
Sega Sammy Holdings Inc
PINK:SGAMF
|
0.023x |
|
PENNON GROUP NEW LS-6105
F:3PN
|
N/A |
|
Bechtle AG
PINK:BHTLF
|
0.064x |
|
Angel Yeast Co Ltd
SHG:600298
|
0.157x |
|
Axfood AB
ST:AXFO
|
0.286x |
|
Seek Ltd
AU:SEK
|
0.064x |
Annual Cash Flow Conversion Efficiency for Dianthus Therapeutics Inc. (2016–2025)
The table below shows the annual cash flow conversion efficiency of Dianthus Therapeutics Inc. from 2016 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $493.40 Million | $-129.06 Million | -0.262x | -17.93% |
| 2024-12-31 | $352.48 Million | $-78.18 Million | -0.222x | -1.61% |
| 2023-12-31 | $168.87 Million | $-36.86 Million | -0.218x | +44.69% |
| 2022-12-31 | $73.66 Million | $-29.07 Million | -0.395x | -14.48% |
| 2021-12-31 | $172.67 Million | $-59.53 Million | -0.345x | +22.51% |
| 2020-12-31 | $143.91 Million | $-64.02 Million | -0.445x | -10.00% |
| 2019-12-31 | $141.19 Million | $-57.10 Million | -0.404x | -40.63% |
| 2018-12-31 | $145.65 Million | $-41.89 Million | -0.288x | +35.00% |
| 2017-12-31 | $50.32 Million | $-22.26 Million | -0.442x | +38.73% |
| 2016-12-31 | $9.04 Million | $-6.53 Million | -0.722x | -- |